References

1. The Global Initiative for Chronic Obstructive Lung Disease. Available at: http://www.goldcopd.com (last accessed 28 April 2011).

2. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease: ATS statement. Am J Respir Crit Care Med 1995;152(suppl):77–120. [Pubmed]

3. Worlh Health Organization. World Health Report 1999. Making a difference. Available at: http://www.who.int/whr/1999/en/index.html (last accessed 28 April 2011).

4. Soriano JB, Maier WC, Egger P, et al. Recent trends in physician diagnosed COPD in women and men in the UK. Thorax 2000;55:789–794. [Pubmed]

5. Whittemore AS, Perlin SA, DiCiccio Y. Chronic obstructive pulmonary disease in lifelong nonsmokers: results from NHANES. Am J Public Health 1995;85:702–706. [Pubmed]

6. Brunekreef B, Fischer P, Remijn B, et al. Indoor air pollution and its effects on pulmonary function of adult non-smoking women: III. passive smoking and pulmonary function. Int J Epidemiol 1985;14:227–230. [Pubmed]

7. Rijcken B, Weiss ST. Longitudinal analyses of airway responsiveness and pulmonary function decline. Am J Respir Crit Care Med 1996;154(suppl):246–249. [Pubmed]

8. Dockery DW, Brunekreef B. Longitudinal studies of air pollution effects on lung function. Am J Respir Crit Care Med 1996;154(suppl):250–256. [Pubmed]

9. O'Connor GT, Sparrow D, Weiss ST. The role of allergy and non-specific airway hyperresponsiveness in the pathogenesis of chronic obstructive pulmonary disease: state of the art. Am Rev Respir Dis 1989;140:225–252. [Pubmed]

10. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the lung health study. JAMA 1994;272:1497–1505. [Pubmed]

11. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD): a consensus statement of the European Respiratory Society. Eur Respir J 1995;8:1398–1420. [Pubmed]

12. Braun SR, McKenzie WN, Copeland W, et al. A comparison of the effect of ipratropium bromide and albuterol in the treatment of chronic obstructive airway disease. Arch Intern Med 1989;149:544–547. [Pubmed]

13. Higgins BG, Powell RM, Cooper S, et al. Effect of salbutamol and ipratropium bromide on airway calibre and bronchial reactivity in asthma and chronic bronchitis. Eur Respir J 1991;4:415–420. [Pubmed]

14. Ikeda A, Nishimura K, Koyama H, et al. Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD: comparison with ipratropium bromide alone. Chest 1995;107:401–405. [Pubmed]

15. Ikeda A, Nishimura K, Koyama H, et al. Comparative dose–response study of three anticholinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease. Thorax 1995;50:62–66. [Pubmed]

16. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999;115:957–965. [Pubmed]

17. Rennard SI, Anderson W, ZuWallack R, et al. Use of a long-acting inhaled beta2 -adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1087–1092. [Pubmed]

18. Dahl R, Greefhorst LA, Nowak D, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:778–784. [Pubmed]

19. Wadbo M, Lofdahl CG, Larsson K, et al. Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study. Eur Respir J 2002;20:1138–1146. [Pubmed]

20. Liesker JJW, Wijkstra PJ, ten Hacken NHT, et al. A systematic review of the effects of bronchodilators on exercise capacity in patients with COPD. Chest 2002;121:597–608. Search date 1999. [Pubmed]

21. Rodrigo GJ, Castro-Rodriguez JA, Nannini LJ, et al. Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis. Respir Med 2009;103:1421–1429. [Pubmed]

22. Rodrigo GJ, Nannini LJ. Tiotropium for the treatment of stable chronic obstructive pulmonary disease: a systematic review with meta-analysis. Pulm Pharmacol Ther 2007;20:495–502. [Pubmed]

23. Kesten S, Jara M, Wentworth C, et al. Pooled clinical trial analysis of tiotropium safety. Chest 2006;130:1695–1703. [Pubmed]

24. Tonnel AB, Perez T, Grosbois JM, et al. Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD. Int J Chron Obstruct Pulmon Dis 2008;3:301–310. [Pubmed]

25. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300:1439–1450. [Pubmed]

26. Sestini P, Renzoni E, Robinson S, et al. Short-acting beta2 agonists for stable chronic obstructive pulmonary disease. In: The Cochrane Library, Issue 2, 2010. Chichester, UK: John Wiley & Sons, Ltd. Search date 2002. [Pubmed]

27. Salpeter SR. Cardiovascular safety of beta2 -adrenoceptor agonist use in patients with obstructive airway disease: a systematic review. Drugs Aging 2004;21:405–414. [Pubmed]

28. Donohue JF, Parsey MV, Andrews C, et al. Evaluation of the efficacy and safety of levalbuterol in subjects with COPD. COPD 2006;3:125–132. [Pubmed]

29. Sin DD, McAlister FA, Man SF, et al. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 2003;290:2301–2312. [Pubmed]

30. Shukla VK, Chen S, Boucher M, et al. Long-acting beta2 agonists for the maintenance treatment of chronic obstructive pulmonary disease in patients with reversible and non-reversible airflow obstruction: a systematic review of clinical effectiveness. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2006. Available at: http://www.cadth.ca/media/pdf/219_LABA_tr_e_no-appendices.pdf (last accessed 28 April 2011).

31. Salpeter SR, Buckley NS, Salpeter EE. Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Int Med 2006;21:1011–1019. [Pubmed]

32. Rodrigo GJ, Nannini LJ, Rodriguez-Roisin R, et al.Safety of long-acting beta-agonists in stable COPD: a systematic review. Chest 2008;133:1079–1087. [Pubmed]

33. Liesker JJ, Van De Velde V, Meysman M, et al. Effects of formoterol (Oxis Turbohaler) and ipratropium on exercise capacity in patients with COPD. Respir Med 2002;96:559–566. [Pubmed]

34. Campbell M, Eliraz A, Johansson G, et al. Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease. Respir Med 2005;99:1511–1520. [Pubmed]

35. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775–789. [Pubmed]

36. O'Donnell DE, Voduc N, Fitzpatrick M, et al. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 2004;24:86–94. [Pubmed]

37. Baumgartner RA, Hanania NA, Calhoun WJ, et al. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Clin Ther 2007;29:261–278. [Pubmed]

38. Beier J, Chanez P, Martinot JB, et al. Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial. Pulm Pharmacol Ther 2007;20:740–749. [Pubmed]

39. Brouillard C, Pepin V. Endurance shuttle walking test: responsiveness to salmeterol in COPD. Eur Respir J 2008;31:579–584. [Pubmed]

40. Hanrahan JP, Grogan DR, Baumgartner RA, et al. Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long-acting beta2-agonists arformoterol and salmeterol. Medicine 2008;87:319–328. [Pubmed]

41. Nelson HS, Gross NJ, Levine B, et al. Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double- blind, double-dummy, placebo- and active-controlled trial. Clin Ther 2007;29:2167–2178. [Pubmed]

42. Hall IP, Tattersfield AE. Beta-agonists. In: Clark TJH, Godfrey S, Lee TH, eds. Asthma. 3rd ed. London: Chapman and Hall Medical, 1992:341–365.

43. Cazzola M, Imperatore F, Salzillo A, et al. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxaemia. Chest 1998;114:411–415. [Pubmed]

44. Appleton S, Jones T, Poole P, et al. Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease. In: The Cochrane Library, Issue 2, 2010. Chichester, UK: John Wiley & Sons, Ltd. Search date 2008. [Pubmed]

45. Appleton S, Jones T, Poole P, et al. Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease. In: The Cochrane Library, Issue 2, 2010. Chichester, UK: John Wiley & Sons, Ltd. Search date 2008.

46. Van Noord JA, de Munck DR, Bantje TA, et al. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 2000;15:878–885. [Pubmed]

47. D'Urzo AD, De Salvo MC, Ramirez-Rivera A, et al. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium: a 3-week, randomized, double-blind, within-patient, multicenter study. Chest 2001;119:1347–1356. [Pubmed]

48. Barr RG, Bourbeau J, Camargo CA, et al. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 2006;61:854–862. [Pubmed]

49. Ram FS. Use of theophylline in chronic obstructive pulmonary disease: examining the evidence. Curr Opin Pulm Med 2006;12:132–139. [Pubmed]

50. Molfino NA, Zhang P. A meta-analysis on the efficacy of oral theophylline in patients with stable COPD. Int J Chron Obstruct Pulmon Dis 2006;1:261–266. [Pubmed]

51. Cazzola M, Gabriella Matera M. The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: a pilot study. Respir Med 2007;101:957–962. [Pubmed]

52. Rossi A, Kristufek P, Levine BE, et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002;121:1058–1069. [Pubmed]

53. Zhou Y, Wang X, Zeng X, et al. Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year. Respirology 2006;11:603–610 [Pubmed]

54. Ramsdell J. Use of theophylline in the treatment of COPD. Chest 1995;107(suppl):206–209. [Pubmed]

55. Callahan CM, Dittus RS, Katz BP. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease: a meta-analysis. Ann Intern Med 1991;114:216–223. Search date 1989. [Pubmed]

56. McEvoy CE, Niewoehner DE. Adverse effects of corticosteroid therapy for COPD: a critical review. Chest 1997;111:732–743. [Pubmed]

57. Langhammer A, Forsmo S, Syversen U, et al. Long-term therapy in COPD: any evidence of adverse effect on bone? Int J Chron Obstruct Pulmon Dis 2009;4:365–380. [Pubmed]

58. Yang IA, Fong KM, Sim EHA, et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. In: The Cochrane Library, Issue 2, 2010. Chichester, UK: John Wiley & Sons, Ltd. Search date 2007. [Pubmed]

59. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002;113:59–65. Search date 2001. [Pubmed]

60. Gartlehner G, Hansen RA, Carson SS, et al. Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. Ann Fam Med 2006;4:253–262. [Pubmed]

61. Agarwal R, Aggarwal AN, Gupta D, et al. Inhaled corticosteroids vs placebo for preventing COPD exacerbations: a systematic review and metaregression of randomized controlled trials. Chest 2010;137:318–325. [Pubmed]

62. Drummond MB, Dasenbrook EC, Pitz MW, et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300:2407–2416. [Pubmed]

63. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:1084–1091. [Pubmed]

64. Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003;124:834–843. [Pubmed]

65. Nannini L, Cates CJ, Lasserson TJ, et al. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. In: The Cochrane Library, Issue 2, 2010. Chichester, UK: John Wiley & Sons, Ltd. Search date 2007. [Pubmed]

66. Tashkin DP, Rennard SI, Martin P, et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs 2008;68:1975–2000. [Pubmed]

67. Zheng JP, Yang L, Wu YM, et al. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD. Chest 2007;132:1756–1763. [Pubmed]

68. Sin DD, Man SF, Marciniuk DD, et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;177:1207–1214. [Pubmed]

69. Nannini LJ, Cates CJ, Lasserson TJ, et al. Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease. In: The Cochrane Library, Issue 2, 2010. Chichester, UK: John Wiley & Sons, Ltd. Search date 2007. [Pubmed]

70. Rodrigo GJ, Castro-Rodriguez JA, Plaza V, et al.Safety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: a systematic review. Chest 2009;136:1029–1038. [Pubmed]

71. Nannini LJ, Cates CJ, Lasserson TJ, et al. Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. In: The Cochrane Library, Issue 2, 2010. Chichester, UK: John Wiley & Sons, Ltd. Search date 2007. [Pubmed]

72. Poole PJ, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. In: The Cochrane Library, Issue 2, 2010. Chichester, UK: John Wiley & Sons, Ltd. Search date 2008. [Pubmed]

73. Grandjean EM, Berthet P, Ruffmann R, et al. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther 2000;22:209–221. Search date 1995. [Pubmed]

74. Zheng JP, Kang J, Huang SG, et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet 2008;371:2013–2018. [Pubmed]

75. Decramer M, Rutten-van Molken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005;365:1552–1560. [Pubmed]

76. Staykova T, Black P, Chacko E, et al. Prophylactic antibiotic therapy for chronic bronchitis. In: The Cochrane Library, Issue 2, 2010. Chichester, UK: John Wiley & Sons, Ltd. Search date not reported.

77. Seemungal TA, Wilkinson TN, Hurst JR, et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008;178:1139–1147. [Pubmed]

78. Cranston JM, Crockett AJ, Moss JR, et al. Domiciliary oxygen in chronic obstructive pulmonary disease. In: The Cochrane Library, Issue 2, 2010. Chichester, UK: John Wiley & Sons, Ltd. Search date 2007. [Pubmed]

79. Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981;1:681–686. [Pubmed]

80. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980;93:391–398. [Pubmed]

81. Heresi GA, Stoller JK. Augmentation therapy in alpha-1 antitrypsin deficiency. Expert Opin Biol Ther 2008;8:515–526. [Pubmed]

82. Dirksen A, Dijkman JH, Madsen F, et al. A randomized clinical trial of alpha1 -antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999;160:1468–1472. [Pubmed]

83. van der Meer RM, Wagena EJ, Ostelo RWJG, et al. Smoking cessation for chronic obstructive pulmonary disease. In: The Cochrane Library, Issue 2, 2010. Chichester, UK: John Wiley & Sons, Ltd. Search date 2007.

84. Wagena EJ, Zeegers MPA, van Schayck CP, et al. Benefits and risks of pharmacological smoking cessation therapies in chronic obstructive pulmonary disease. Drug Safety 2003;26:381–403. Search date 2002. [Pubmed]

85. Anthonisen NR, Connett JE, Enright PL, et al. Hospitalizations and mortality in the lung health study. Am J Respir Crit Care Med 2002;166:333–339. [Pubmed]

86. O'Hara P, Grill J, Rigdon M, et al. Design and results of the intervention program for the Lung Health Study. Prev Med 1993;22:304–315. [Pubmed]

87. Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality. A randomized trial. Ann Intern Med 2005;142:233–239. [Pubmed]

88. Anthonisen NR, Connett JE, Murray RP for the Lung Health Study Research Group. Smoking and lung function of the lung health study participants after 11 years. Am J Respir Crit Care Med 2002;166:675–679. [Pubmed]

89. Kanner RE, Connett JE, Williams DE, et al. Effects of randomized assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in smokers with early chronic obstructive pulmonary disease: the Lung Health Study. Am J Med 1999;106:410–416. [Pubmed]

90. Murray RP, Bailey WC, Daniels K, et al. Safety of nicotine polacrilex gum used by 3,094 participants in the Lung Health Study. Lung Health Study Research Group. Chest 1996;109:438–445. [Pubmed]

91. O'Hara P, Connett JE, Lee WW, et al. Early and late weight gain smoking cessation in the lung health study. Am J Epidemiol 1998;148:821–830. [Pubmed]

92. Tashkin D, Kanner R, Bailey W, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001;357:1571–1575. [Pubmed]

93. National Institute for Health and Clinical Excellence. Guidance on the use of nicotine replacement therapy (NTR) and bupropion for smoking cessation. March 2002. Available at: http://www.nice.org.uk/Guidance/TA39 (last accessed 28 April 2011).

94. National Institute for Clinical Excellence. A rapid and systematic review of the clinical and cost effectiveness of bupropion SR and nicotine replacement therapy (NTR) for smoking cessation. NHS Centre for Reviews & Dissemination, University of York (UK), February 2002.

95. Kanner RE, Anthonisen NR, Connett JE, et al. Lower respiratory illnesses promote FEV1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med 2001;164:358–364. [Pubmed]

96. Murray RP, Connett JE, Rand RCR, et al. Persistence of the effect of the Lung Health Study (LHS) smoking intervention over eleven years. Prev Med 2002;35:314–319. [Pubmed]

97. Lacasse YL, Brosseau S, Milne S, et al. Pulmonary rehabilitation for chronic obstructive pulmonary disease. In: The Cochrane Library, Issue 2, 2010. Chichester, UK: John Wiley & Sons, Ltd. Search date 2004.

98. Salman GF, Mosier MC, Beasley BW, et al. Rehabilitation for patients with chronic obstructive pulmonary disease: meta-analysis of randomized controlled trials. J Gen Intern Med 2003;18:213–221. [Pubmed]

99. Guell R, Resqueti V, Sangenis M, et al. Impact of pulmonary rehabilitation on psychosocial morbidity in patients with severe COPD. Chest 2006;129:899–904. [Pubmed]

100. Paz-Diaz H, Montes de Oca M, Lopez JM, et al. Pulmonary rehabilitation improves depression, anxiety, dyspnea and health status in patients with COPD. Am J Phys Med Rehab 2007;86:30–36. [Pubmed]

101. Theander K, Jakobsson P, Jorgensen N, et al. Effects of pulmonary rehabilitation on fatigue, functional status and health perceptions in patients with chronic obstructive pulmonary disease: a randomized controlled trial. Clin Rehabil 2009;23:125–136. [Pubmed]

102. Karapolat H, Atasever A, Atamaz F, et al. Do the benefits gained using a short-term pulmonary rehabilitation program remain in COPD patients after participation? Lung 2007;185:221–225. [Pubmed]

103. Coventry PA, Hind D. Comprehensive pulmonary rehabilitation for anxiety and depression in adults with chronic obstructive pulmonary disease: systematic review and meta-analysis. J Psychosom Res 2007;63:551–565. [Pubmed]

104. Ghanem M, Elaal EA, Mehany M, et al. Home-based pulmonary rehabilitation program: effect on exercise tolerance and quality of life in chronic obstructive pulmonary disease patients. Ann Thorac Med 2010;5:18–25. [Pubmed]

105. Elci A, Borekci S, Ovayolu N, et al. The efficacy and applicability of a pulmonary rehabilitation programme for patients with COPD in a secondary-care community hospital. Respirology 2008;13:703–707. [Pubmed]

106. Lotters F, van Tol B, Kwakkel G, et al. Effects of controlled inspiratory muscle training in patients with COPD: a meta-analysis. Eur Respir J 2002;20:570–576. [Pubmed]

107. Geddes EL, Reid WD, Crowe J, et al. Inspiratory muscle training in adults with chronic obstructive pulmonary disease: a systematic review. Respir Med 2005;99:1440–1458. [Pubmed]

108. Geddes EL, O'Brien K, Reid WD, et al. Inspiratory muscle training in adults with chronic obstructive pulmonary disease: an update of a systematic review. Respir Med 2008;102:1715–1729. [Pubmed]

109. O'Shea SD, Taylor NF, Paratz JD. Progressive resistance exercise improves muscle strength and may improve elements of performance of daily activities for people with COPD: a systematic review. Chest 2009;136:1269–1283. [Pubmed]

110. Janaudis-Ferreira T, Hill K, Goldstein R, et al. Arm exercise training in patients with chronic obstructive pulmonary disease: a systematic review. J Cardiopulm Rehabil Prev 2009;29:277–283. [Pubmed]

111. Costi S, Di BariM, Pillastrini P, et al. Short-term efficacy of upper-extremity exercise training in patients with chronic airway obstruction: a systematic review. Phys Ther 2009;89:443–455. [Pubmed]

112. Chavannes N, Vollenberg JJ, van Schayck CP, et al. Effects of physical activity in mild to moderate COPD: a systematic review. Br J Gen Pract 2002;52:574–578. [Pubmed]

113. Hospes G, Bossenbroek L, Ten Hacken NH, et al. Enhancement of daily physical activity increases physical fitness of outclinic COPD patients: results of an exercise counseling program. Patient Educ Couns 2009;75:274–278. [Pubmed]

114. Cambach W, Chadwick-Straver RV, Wagenaar RC, et al. The effects of a community-based pulmonary rehabilitation programme on exercise tolerance and quality of life: a randomized controlled trial. Eur Respir J 1997;10:104–113. [Pubmed]

115. Ringbaek TJ, Broendum E, Hemmingsen L, et al. 2000. Rehabilitation of patients with chronic obstructive pulmonary disease. Exercise twice a week is not sufficient! Respir Med 2000;94:150–154. [Pubmed]

116. Ferreira I, Brooks D, Lacasse Y, et al. Nutritional supplementation for stable chronic obstructive pulmonary disease. In: The Cochrane Library, Issue 2, 2010. Chichester, UK: John Wiley & Sons, Ltd. Search date 2006.

117. Ferreira I, Brooks D, Lacasse Y, et al. Nutritional intervention in COPD: a systematic overview. Chest 2001;119:353–363. [Pubmed]

118. Schols AMWJ, Brug J. Efficacy of nutritional intervention in chronic obstructive pulmonary disease. In: Wouters EFM, Schols AMWJ, eds. European Respiratory Monograph: Nutrition and Metabolism in Chronic Respiratory Disease, Volume 8, monograph 24.